Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).

Abstract

5016Background: Androgen deprivation therapy (ADT) with GnRH analogs does not entirely suppress androgen signaling. AAP + ADT decreases blood and intratumoral testosterone (T) levels by ≥1 log, and...